Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from EKF Diagnostics Holdings ( (GB:EKF) ).
EKF Diagnostics Holdings has completed its share buyback programme, purchasing a final tranche of 159,000 ordinary shares at a weighted average price of 25.6875 pence, bringing total repurchases under the scheme to 17.13 million shares at an average cost of 26.14 pence, with the latest shares held in treasury. Following these transactions, EKF’s issued share capital stands at 435.38 million shares, of which 431.96 million carry voting rights, while a related trade with funds managed by Harwood ensures non-executive director Christopher Mills’ aggregate indirect stake remains at about the same level and below 30% of voting rights, clarifying the ownership structure for investors and the threshold for regulatory disclosures.
The most recent analyst rating on (GB:EKF) stock is a Hold with a £29.00 price target. To see the full list of analyst forecasts on EKF Diagnostics Holdings stock, see the GB:EKF Stock Forecast page.
Spark’s Take on GB:EKF Stock
According to Spark, TipRanks’ AI Analyst, GB:EKF is a Neutral.
EKF Diagnostics Holdings receives a score of 67, driven by strong financial performance and a positive earnings call. The company’s robust balance sheet and improved profitability are significant strengths. However, technical indicators suggest potential bearish momentum, and the valuation is moderate. The positive outlook from the earnings call, including strategic growth plans and a share buyback program, enhances the overall score.
To see Spark’s full report on GB:EKF stock, click here.
More about EKF Diagnostics Holdings
EKF Diagnostics Holdings is an AIM-listed global diagnostics business specialising in point‑of‑care analysers for haematology and diabetes, as well as life sciences services that include specialist enzyme manufacture and custom products for diagnostic, food and industrial applications. Headquartered in Penarth near Cardiff, the company operates five manufacturing sites across the US and Germany and sells into more than 120 countries worldwide.
Average Trading Volume: 336,911
Technical Sentiment Signal: Sell
Current Market Cap: £106.3M
For a thorough assessment of EKF stock, go to TipRanks’ Stock Analysis page.